Belpointe Asset Management LLC Reduces Position in Thermo Fisher Scientific Inc. $TMO

Belpointe Asset Management LLC lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.5% in the second quarter, HoldingsChannel reports. The firm owned 5,276 shares of the medical research company’s stock after selling 551 shares during the period. Belpointe Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $2,139,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Valley National Advisers Inc. boosted its stake in shares of Thermo Fisher Scientific by 1.5% during the 2nd quarter. Valley National Advisers Inc. now owns 3,282 shares of the medical research company’s stock valued at $1,329,000 after buying an additional 50 shares during the last quarter. Duncan Williams Asset Management LLC bought a new position in Thermo Fisher Scientific during the 2nd quarter valued at $206,000. DAVENPORT & Co LLC grew its holdings in Thermo Fisher Scientific by 8.1% during the 2nd quarter. DAVENPORT & Co LLC now owns 5,048 shares of the medical research company’s stock worth $2,047,000 after acquiring an additional 380 shares in the last quarter. Marks Group Wealth Management Inc increased its position in shares of Thermo Fisher Scientific by 3.2% in the 2nd quarter. Marks Group Wealth Management Inc now owns 9,692 shares of the medical research company’s stock worth $3,930,000 after purchasing an additional 305 shares during the last quarter. Finally, Grimes & Company Inc. lifted its position in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Grimes & Company Inc. now owns 16,143 shares of the medical research company’s stock worth $6,545,000 after purchasing an additional 144 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on TMO shares. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating on the stock. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Finally, HSBC reaffirmed a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $585.37.

Thermo Fisher Scientific Trading Up 0.2%

Shares of NYSE:TMO opened at $544.44 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $483.77 and its 200 day moving average price is $446.95. The company has a market cap of $205.59 billion, a PE ratio of 31.49, a P/E/G ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.